DGAP-News: Biotest AG
/ Key word(s): Personnel
09.12.2021 / 12:51
The issuer is solely responsible for the content of this announcement.
Biotest Supervisory Board appoints new Management Board member
– Dr Jörg Schüttrumpf appointed to the Board as Chief Scientific Officer (CSO)
– Development of trimodulin and Fibrinogen to be accelerated
– Additional phase III trial with Covid-19 patients
Dreieich, 9 December 2021. At its meeting today, the Supervisory Board of Biotest AG appointed Dr Jörg Schüttrumpf (47) as a further member of the company’s Management Board with effect from 1 January 2022.
As ‘Chief Scientific Officer’, Dr Schüttrumpf will be responsible within the Biotest Group for the area of research and development, including drug safety and drug approval. Dr Schüttrumpf has been responsible for global research at Biotest AG since 2012 and for research and development since 2015.
This personnel decision is directly accompanied by the Supervisory Board’s approval of an expanded budget for the accelerated development of trimodulin in sCAP and of Fibrinogen also for the USA. In addition, the Supervisory Board approved the start of an additional phase III trial with trimodulin in Covid-19 patients, which had not previously been planned. As announced on 23 November 2021, this development will be funded by the German Federal Ministry of Education and Research (BMBF) and the German Federal Ministry of Health (BMG). Biotest will have to bear 20% of the funds required for this study itself.
“We are happy that Dr Schüttrumpf will be joining the Board of Biotest AG in the future. He has been very successful in developing research and development at Biotest and is a management personality with an impressive professional vitae. His appointment strengthens the company’s strategic focus on growth as a provider of innovative plasma therapeutics,” emphasises Rolf Hoffmann, Chairman of the Supervisory Board of Biotest AG.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1256048|
|End of News||DGAP News Service|